Journal
XENOBIOTICA
Volume 48, Issue 1, Pages 37-44Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/00498254.2016.1278287
Keywords
Acute kidney injury; anemia; erythropoietin; nephrectomy; pharmacokinetics; ZYAN1
Categories
Ask authors/readers for more resources
1. ZYAN1 is a prolyl hydroxylase inhibitor in clinical development for treatment of anemia associated with chronic kidney disease (CKD). We evaluated the effect of acute and chronic kidney impairment on the pharmacokinetics of ZYAN1 in rat models. 2. Cisplatin (2.5, 5 and 7.5 mg/kg) was used to induce acute kidney injury (AKI), and five-sixth and total nephrectomy was used to induce chronic kidney injury (CKI) in male Wistar rats. All groups received a single 15 mg/kg oral dose of ZYAN1. Blood/urine samples were analyzed for ZYAN1 to assess peak concentration (C-max), area under the concentration-time curve (AUC(inf)), total body clearance (CL/F) and elimination half-life (T-1/2). 3. C-max and AUC(inf) were not significantly different in the various AKI groups or in five-sixth nephrectomized rats, as compared to control rats. Recovery of ZYAN1 in urine was reduced; the impact on the CL/F was minimal. There was a 2-fold increase in AUC(inf) with reduction in CL/F in total nephrectomized rats. T-1/2 was longer for ZYAN1 in the severe AKI/five-sixth nephrectomy rats and total nephrectomy rats as compared to control rats. 4. Based on the rodent data it may be inferred that PK of ZYAN1 in CKD patients may be minimally affected.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available